Eikon Therapeutics is pioneering a new method of drug discovery based on tracking and measuring
the movement of individual proteins in living cells.

Eikon’s live cell imaging drug discovery platform is built on groundbreaking innovations from its founders who pioneered the field of in vivo single-molecule microscopy, and whose work was awarded the Nobel Prize in Chemistry in 2014.

• Industry

  • 3D Imaging
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2019

• Founders

  • Eric Betzig
  • Robert Tjian
  • Luke Lavis
  • Xavier Darzacq

  LUX Partners

  • Adam Goulburn

• Latest Tweets

  • We are pleased to announce that Eikon Therapeutics, Inc. has received an award from Endpoints as "One of Biopharma'… https://t.co/GO9oRWoQM2@EikonTX - 05:13 PM Sep 22nd
  • Eikon is excited to announce today that Alfred Bowie Jr, PhD has joined us as our Chief Financial Officer! (1/3) https://t.co/nh4jFlnA4p@EikonTX - 02:53 PM Jun 29th
  • .@lisamjarvis covered our drug discovery platform, which combines optical tools, gene-editing, #MachineLearning and… https://t.co/FPk9Rafg37@EikonTX - 04:51 PM May 11th